Steven H. Koehler Purchases 5,000 Shares of Teligent, Inc. (TLGT) Stock
Teligent, Inc. (NASDAQ:TLGT) Director Steven H. Koehler acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average cost of $3.62 per share, for a total transaction of $18,100.00. Following the completion of the transaction, the director now directly owns 1,800 shares in the company, valued at approximately $6,516. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Teligent, Inc. (TLGT) traded up $0.62 on Monday, reaching $3.74. 2,751,000 shares of the company’s stock traded hands, compared to its average volume of 1,031,454. The company has a current ratio of 4.37, a quick ratio of 3.71 and a debt-to-equity ratio of 1.99. Teligent, Inc. has a 1-year low of $2.82 and a 1-year high of $9.54.
Teligent (NASDAQ:TLGT) last issued its quarterly earnings data on Monday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.07). Teligent had a negative return on equity of 6.38% and a negative net margin of 16.95%. The business had revenue of $13.65 million during the quarter, compared to the consensus estimate of $19.12 million. During the same quarter last year, the company earned $0.01 EPS. Teligent’s revenue for the quarter was down 15.5% on a year-over-year basis. analysts expect that Teligent, Inc. will post -0.13 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Steven H. Koehler Purchases 5,000 Shares of Teligent, Inc. (TLGT) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/11/13/steven-h-koehler-purchases-5000-shares-of-teligent-inc-tlgt-stock.html.
Several research firms have issued reports on TLGT. Roth Capital set a $9.00 target price on shares of Teligent and gave the company a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research cut shares of Teligent from a “hold” rating to a “strong sell” rating in a research note on Saturday. Canaccord Genuity cut shares of Teligent from a “buy” rating to a “hold” rating and lowered their target price for the company from $9.00 to $5.00 in a research note on Tuesday, November 7th. BidaskClub cut shares of Teligent from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Finally, TheStreet cut shares of Teligent from a “c-” rating to a “d+” rating in a research note on Wednesday, November 1st. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $7.33.
Teligent Company Profile
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.